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Abstract 
 
Nature is the major reservoir of biologically active molecules. The urgent need of finding 
novel molecules with pharmaceutical interest is prompting the research of underexplored 
environments, such as marine ecosystems. In this regard, marine actinobacteria 
represent a remarkable source of biologically active compounds. Marine actinobacteria 
often live in association with other organisms, representing unique ecological niches for 
the discovery of new bioactive substances. Despite the proven potential of actinobacteria 
as source of secondary metabolites with pharmacologically-relevant activities, only few 
studies have focused on actinobacteria associated with macroalgae. This study aimed 
to investigate the cultivable community of endophytic actinobacteria associated with the 
macroalgae Laminaria ochroleuca and assess its potential to produce compounds with 
antimicrobial and anticancer activities. Fragments of tissues from different parts of L. 
ochroleuca (holdfast, stipe and blade), collected in a rocky shore in northern Portugal, 
were surface sterilized and plated in three culture media selective for actinobacteria. A 
total of 90 actinobacterial strains were isolated, with the majority being affiliated with the 
genus Streptomyces. Isolates associated with the genera Isoptericola, Rhodococcus, 
Nonomuraeae, Nocardiopsis, Microbispora and Microbacterium were also obtained. 
Extracts from all actinobacterial isolates were tested for their antimicrobial activity using 
the agar-based disk diffusion method, followed by determination of MIC values for 
extracts showing relevant activities. Forty-five isolates inhibited, to some degree, the 
growth of Candida albicans and/or Staphylococcus aureus, with MIC values ranging from 
< 0.487 to 1000 µg/mL. The actinobacterial isolates were also tested for their anticancer 
potential in two human carcinogenic cell lines (breast carcinoma T-47D and 
neuroblastoma SH-SY5Y) and compared to their cytotoxicity on a non-carcinogenic 
endothelial cell line (hCMEC/D3). Thirty isolates exhibited anticancer activity in at least 
one of the tested cell lines, decreasing their viability to less than 50%. Four isolates were 
identified with strong cytotoxic activity on SH-SY5Y cells, but with low activity on 
hCMEC/D3 cells. According to LC-MS/MS dereplication data, the activity of most extracts 
may be associated with the presence of secondary metabolites antimycins. The active 
strain Streptomyces sp. KENR25 was selected for a bioassay-guided fractionation, 
following part of a traditional natural product discovery pipeline, with several fractions 
showing mainly antimicrobial activity. This study reveals that L. ochroleuca is a rich 
source of actinobacteria with promising antimicrobial and anticancer activities and further 
supports that macroalgae may be a valuable resource of actinobacteria and, 
consequently, of new molecules with biotechnological importance. 
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Resumo 
 
A natureza constitui o maior reservatório de moléculas biologicamente ativas. A urgente 
necessidade de encontrar novas moléculas com interesse farmacêutico tem incentivado 
a investigação de ambientes pouco explorados, como os ecossistemas marinhos. Neste 
sentido, as actinobactérias marinhas são uma fonte notável de compostos 
biologicamente ativos. As actinobactérias marinhas vivem muitas vezes em associação 
com variados organismos, representando nichos ecológicos únicos para a descoberta 
de novas substâncias bioativas. Apesar do enorme potencial das actinobactérias como 
fonte de metabolitos secundários com atividades farmacológicas relevantes, poucos 
estudos se têm focado no potencial de actinobactérias associadas a macroalgas. Este 
estudo teve como objetivo investigar a comunidade cultivável de actinobactérias 
endófitas associadas à macroalga Laminaria ochroleuca e avaliar o seu potencial para 
produzir compostos com atividades antimicrobiana e anticancerígena. Fragmentos de 
tecidos de diferentes partes da alga L. ochroleuca (rizoide, estipe e lâmina), recolhida 
na costa rochosa norte de Portugal, foram esterilizados na sua superfície e plaqueados 
em três meios de cultura seletivos para actinobactérias. Um total de 90 estirpes de 
actinobactérias foram isoladas, estando a a maioria afiliada com o género Streptomyces. 
Isolados associados com os géneros Isoptericola, Rhodococcus, Nonomuraeae, 
Nocardiopsis, Microbispora e Microbacterium também foram obtidos. Todos os extratos 
actinobacterianos foram testados quanto à sua atividade antimicrobiana usando o 
método de difusão em agar, seguindo-se a determinação do MIC para extratos com 
atividade relevante. Quarenta e cinco isolados inibiram o crescimento de Candida 
albicans e/ou Staphylococcus aureus, com valores de MIC entre < 0.487 e 1000 µg/mL. 
O potencial anticancerigeno dos isolados foi também testado em duas linhas celulares 
carcinogénicas humanas (carcinoma da mama T-47D e neuroblastoma SH-SY5Y) e a 
sua citotoxicidade comparada numa linha celular não-carcinogénica (hCMEC/D3). Trinta 
isolados exibiram atividade anticancerígena em pelo menos uma das linhas celulares 
testadas, diminuindo a viabilidade das células para menos de 50%. Quatro isolados 
foram identificados com uma forte atividade citotóxica nas células SH-SY5Y, mas com 
pouca atividade nas células hCMEC/D3. De acordo com os dados de desreplicação, a 
atividade da maioria dos extratos está associada com a presença dos metabolitos 
secundários antimicinas. A estirpe ativa KENR25 foi selecionada para um fracionamento 
guiado por ensaios de bioatividade, seguindo parte do procedimento tradicional para a 
descoberta de produtos naturais, onde várias frações mostraram principalmente 
atividade antimicrobiana. Este estudo revela que a alga L. ochroleuca é uma fonte rica 
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de actinobactérias com promissoras atividades antimicrobianas e anticancerígenas, 
suportando a ideia de que as macroalgas podem ser um recurso valioso de 
actinobactérias e, consequentemente, de novas moléculas com importância 
biotecnológica.  
 
 
Palavras-chave 
actinobactérias marinhas, actinobactérias endófitas, bioatividade, atividade 
antimicrobiana, atividade anticancerígena, macroalga, kelp, Laminaria ochroleuca  
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I. Introduction 
 
 
Human health is constantly and increasingly under the threat of several disorders that 
demand urgent solutions, such as cancer pathologies or the increasing incidence of 
antibiotic multi-resistant microbial species. The search for novel bioactive compounds is 
an effective approach to tackle this problematic, with the natural environment still being 
the major source to find such molecules [1, 2]. Taking cancer as an example, from 1940 
to the end of 2014, about half of the approved drugs for combating this disease were 
either natural products (NPs) or compounds directly derived from them [3]. Among the 
different natural sources from which bioactive molecules may derive, microorganisms 
play a prominent role: from bacteria to fungi, microorganisms have proved their ability to 
produce a wide range of NPs exhibiting numerous biological activities [4]. Within the 
domain Bacteria, the phylum Actinobacteria plays a major role in the production of 
bioactive compounds, especially the species belonging to the order Actinomycetales, 
commonly known as actinomycetes. So far, more than 10.000 different bioactive 
compounds produced by actinomycetes have been identified, representing about 50% 
of all bioactive metabolites obtained from microorganisms, with most of them being 
derived from the genus Streptomyces and a smaller fraction from the so-called rare 
actinomycetes [5, 6]. From the pharmaceutical, biotechnological, industrial and economic 
point of view, actinomycetes are amongst the most valuable microorganisms, being 
capable of producing antibiotics, antimicrobials, anti-inflammatory, anticancer and 
antitumor agents, immunosuppressive compounds, etc. [3, 7]. Despite the wide range of 
known bioactive compounds and their significant applications, the discovery of new 
natural molecules is coming to a stagnation point. However, this reality is not in 
agreement with the data obtained from genomic analysis which suggest that only about 
10% of microbial secondary metabolites are known [8]. The decrease in the discovery of 
new bioactive compounds and the increase in the re-isolation of known ones, may be 
explained by the fact that in the last decades, most of the bioactivity screening 
programmes have focused on highly explored environments, mainly terrestrial ones [7, 9]. 
Considering the need of finding novel secondary metabolites with bioactive action, it is 
highly promising to investigate actinobacteria from unexplored or underexplored 
habitats, such as the marine environment. The conditions found in marine environments 
are very different from those  occurring in terrestrial ones, which translates in different 
microbial evolutionary mechanisms and, consequently, in different metabolisms that may 
lead to the production of novel differentiated chemical molecules [10]. 
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1. Phylum Actinobacteria 
 
Actinobacteria are filamentous Gram-positive bacteria, usually with a high guanine/ 
cytosine content in their DNA that can vary between 50% and 70% according to the 
species. The phylum Actinobacteria represents one of the largest taxonomic units within 
the domain Bacteria, both in number and diversity, including 6 classes, 25 orders, 52 
families, and 232 genera [7, 11]. Microorganisms belonging to this phylum exhibit a wide 
variety of morphologies, from coccoid to fragmenting hyphal forms or highly differentiated 
branched mycelium, with several species being able to reproduce by sporulation. 
Actinobacteria species also exhibit diverse metabolic, physiological and ecological 
properties that result in the production of several secondary metabolites, many with 
biological activity [11]. These microorganisms are widely disseminated in both terrestrial 
and aquatic habitats, including marine ecosystems. They are usually more common in 
the soil where they play an important role in the recycling of organic matter but can also 
be found as plant symbionts (e.g., Frankia sp.), animal or plant pathogens (e.g., 
Corynebacterium sp., Mycobacterium sp., Propionibacterium sp. and Nocardia sp.) or 
even gastrointestinal commensals (e.g., Bifidobacterium sp.) [11, 12]. Since the 1950s, 
Actinobacteria from different sources, fundamentally from terrestrial ecosystems, have 
been studied for their high potential to produce bioactive compounds, resulting in the 
discovery of a wide range of clinically-relevant compounds. Anticancer, antitumor or 
antibacterial compounds are representative examples of the wide range of biological 
active molecules produced by these microorganisms [13, 14]. Actinobacteria also have a 
role as plant growth-promoting agents [15, 16] and play an important part in bioremediation 
processes, since they are able to metabolize complex organic compounds and to remove 
xenobiotics, such as pesticides and heavy metals, from the environment [17, 18]. One other 
characteristic of these microorganisms is their ability to produce and accumulate 
polyhydroxyalkanoates (PHAs), biodegradable and renewable polymers that may be 
used to produce disposable and biodegradable plastics or as scaffold material for tissue 
engineering or controlled drug delivering [19]. Given the immense biotechnological, 
industrial, ecological and biopharmaceutical applications of Actinobacteria, there is high 
interest in studying these microorganisms as potential sources of new compounds. 
Within the phylum Actinobacteria, the order Actinomycetales comprehends most of the 
taxonomic units responsible for the synthesis of bioactive secondary metabolites, and 
the terms actinobacteria or actinomycetes will be hereafter used as synonymous of 
microorganisms affiliated with this order. Among these taxonomic units, the genus 
Streptomyces is particularly relevant as these microorganisms are considered the 
primary producers of antibiotics, being highly exploited by the pharmaceutical industry, 
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with almost all the natural antibiotics currently in clinical use being derived from 
secondary metabolites of these bacteria [6, 20]. Recognizing the unmatched potential of 
actinomycetes to produce compounds with relevant bioactivities, these organisms 
continue to be primary targets to discover novel useful natural products [21].  
 
2. Marine Actinobacteria 
 
Historically, actinobacteria were thought to inhabit exclusively terrestrial environments 
and it was believed that their occurrence in the oceans was due to the transport of 
terrestrial spores to those regions. Today, it is known that this is false and that 
actinobacteria are widely distributed in the marine environment, with several indigenous 
marine actinobacteria being described. Among several others, representative genera of 
marine actinobacteria include Actinomadura, Aeromicrobium, Dietzia, Gordonia, 
Marinophilus, Micromonospora, Nonomuraea, Rhodococcus, Saccharomonospora, 
Salinispora, Streptomyces, Solwaraspora, Williamsia, and Verrucosispora [7]. Although 
their prevalence in sediments, they also exist in association with fishes, sponges, 
seaweeds or corals (Fig. 1) [7, 22]. Nevertheless, the ecological role, diversity, distribution 
and bioactive potential of marine actinobacteria are still largely unknown and require 
further study [13, 23]. The environmental conditions found in marine ecosystems are very 
different from terrestrial ones, driving unparalleled evolutionary mechanisms. For marine 
actinobacteria, this is reflected in novel capacities to produce secondary metabolites [7]. 
Given the fact that the discovery of novel bioactive compounds is reaching a stagnation 
point, marine actinobacteria pose as a promising source of novel natural products [13].   
 
Figure 1. Distribution of actinobacteria in the marine environment, according to a total of 10 400 
16S rRNA gene sequences retrieved from marine actinobacteria. Adapted from [22]. 
 
Sediments…
Sponges (22%)
Corals (6%)
Sea Water (3%)
Tunicates (1%)
Seaweeds (1%)
Fishes (1%)
Other (11%)
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3. Marine Actinobacteria as a Source of Bioactive 
Compounds 
 
The discovery of new drugs to help treating serious human diseases is a constant 
demanding and, in this respect, marine actinobacteria constitute a precious source for 
the search of these so needed compounds [1]. It is known that the biosynthesis of these 
compounds is usually triggered by a wide variety of environmental and physiological 
signals [24] and, since the last decade, marine actinobacteria have been attracting the 
attention of the scientists for their ability to produce novel compounds with antibacterial, 
antifungal, antiviral, antitumor, anticancer, cytotoxic, anti-inflammatory, anti-parasitic, 
anti-malarial and immunosuppressive activities [13, 14, 25, 26]. Table 1 presents a summary 
of bioactive compounds reported from marine actinobacteria, until 2017.  
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Table 1. Bioactive metabolites produced by marine actinobacteria, until 2017 (Adapted from [13, 14, 25]) 
 
Compound Source Biological Activity Ref 
    
Abyssomycins Verrucosispora sp. Antibacterial [27] 
Actinofuranones Streptomyces sp. Cytotoxic [28] 
Ammosamides Streptomyces sp.  Cytotoxic [29] 
Antimycin A Streptomyces sp. Antifungal; Anticancer;  
Anti-inflammatory;  
[30] 
Arenamides Salinipora arenicola Cytotoxic [31] 
Arenicolides Salinispora arenicola Antitumor [32] 
Aureolic acid Streptomyces sp. Antitumor; Antibacterial [33] 
Aureoverticillactam Streptomyces 
aureoverticillatus 
Anticancer [34] 
Avermectins Streptomyces avermitilis Anti-parasitic [35] 
Benzastatin C Streptomyces nitrosporeus Antiviral  [36] 
Bisanthraquinone Streptomyces sp. Antibacterial [37] 
Bonactin Streptomyces sp. Antibacterial; Antifungal [38] 
Butenolides Streptomyces sp. Antiviral; Cytotoxic [39] 
Caboxamycin Streptomyces sp.  Anticancer [40] 
Caprolactones  Streptomyces sp. Anticancer [41] 
Chalcomycin A Streptomyces sp.  Antibacterial [42] 
Chandrananimycins Actinomadura sp. Antibacterial; Antifungal; 
Anticancer 
[43] 
Chartreusin Streptomyces chartreusis Antitumor [44] 
Chinikomycins Streptomyces sp. Anticancer [45] 
Chloro-dihydroquinones Novel actinomycete Antibacterial; Anticancer [46] 
Chromomycins Streptomyces griseus Antitumor [33] 
Curvularin-7-O-
dglucopyranoside 
Pseudonocardia sp. Antibacterial; Anticancer [47] 
Cyclomarin A Streptomyces sp. Anti-inflammatory; Anti-Malarial;  
Anti-Tuberculosis 
[48] 
Daryamides Streptomyces sp.  Antitumor; Antifungal [49] 
Diazepinomicin  Micromonospora sp. Antibacterial; Anticancer;  
Anti-inflammatory 
[50] 
Essramycin Streptomyces sp.  Antibacterial [51] 
Frigocyclinone Streptomyces griseus Antibacterial [52] 
Glaciapyrroles Streptomyces sp. Antibacterial [53] 
Gutingimycin Streptomyces sp. Antibacterial [54] 
Helquinoline Janibacter limosus Antibacterial [55] 
Himalomycins A, B Streptomyces sp. Antibacterial [56] 
IB-00208 Actinomadura sp. Anticancer [57] 
Komodoquinone A Streptomyces sp. Neuritogenic activity [58] 
Lajollamycin Streptomyces nodosus Antibacterial [59] 
Lagumycin B Micromonospora sp.  Antibacterial; Cytotoxic [60] 
Leptomycin B Streptomyces sp. Anti-Parasitic [61] 
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Lipoxazolidinones A, B Marinispora sp. Antibacterial [62] 
Lucentamycins Nocardiopsis lucentensis Cytotoxic [63] 
Lynamicins Marinispora sp. Antibacterial [64] 
Manumycins Streptomyces sp. Antibacterial; Antitumor [45] 
Mansouramycin C Streptomyces sp. Cytotoxic [65] 
Marinomycins Marinispora sp. Antibacterial; Cytotoxic;  [66] 
Marinopyrroles Streptomyces sp.  Antibacterial; Anticancer [67] 
Mechercharmycins Thermoactinomyces sp. Anticancer [68] 
Monacyclinones Streptomyces sp. Antibacterial; Cytotoxic [69] 
N-acetyl-N-
demethylmayamycin 
Streptomyces sp. Antibacterial; Antitumor [70] 
Neomarinone Strain CNH-099 C Cytotoxic [71] 
N-(2-hydroxyphenyl)-2- 
phenazinamine (NHP) 
Nocardia dassonvillei Antifungal; Anticancer [72] 
Pacificanones Salinispora pacifica  Cytotoxic [73] 
Phenazines 1,2 Streptomyces sp. Anti-inflammatory; Anticancer [74] 
Piericidins Streptomyces sp. Anticancer [75] 
Piperazimycins Streptomyces sp. Cytotoxic [76] 
Proximicins Verrucosispora sp. Cytostatic [77] 
Pyridinium Amycolatopsis alba Antibacterial; Cytotoxic [78] 
Resistoflavine Streptomyces chibaensis Cytotoxic  [79] 
Saadamycin Streptomyces sp. Antifungal [80] 
Salinamides Streptomyces sp. Antibacterial; Anti-inflammatory [81] 
Saliniketals Salinispora arenicola Anticancer [32] 
Salinisporamycin Salinispora arenicora Antibacterial; Cytotoxic [82] 
Salinipyrones Salinispora pacifica  Cytotoxic [73] 
Salinosporamide A* Salinispora tropica Anticancer [83] 
Selina-4(14),7(11)-diene-
8,9-dio 
Streptomyces sp.  Anticancer [84] 
Sisomicin Streptomyces sp.  Antibacterial [85] 
Staurosporine Streptomyces sp. Anti-parasitic [86] 
Strepsesquitriol Streptomyces sp. Anticancer [87] 
Streptoanthraquinone A Streptomyces sp. Antibacterial; Anticancer  [70] 
Streptochlorin Streptomyces sp.  Anticancer [88] 
Streptokordin Streptomyces sp.  Anticancer [89] 
Streptomyceamide C Streptomyces sp. Cytotoxic [90] 
Thalassospiramides A, B Thalassospira sp. Immune-suppressive [91] 
Thiocoraline Micromonospora sp. Antitumor; Antimicrobial [92] 
Tirandamycin C Streptomyces sp. Antibacterial [93] 
Trioxacarcins Streptomyces sp. Antibacterial; Anticancer;  
Anti-Malarial 
[94] 
Valinomycin Streptomyces sp. Anti-Parasitic [86] 
Violapyrones Streptomyces sp. Antibacterial; Cytotoxic  [95] 
*compound in phase I of clinical trials for the treatment of human lymphoma and multiple myeloma 
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3.1. Antimicrobial Activity 
 
The increasing of antibiotic-resistant bacteria is a worldwide problem and a worrying 
phenomenon. The microbial resistance to antibiotics, is mainly attributed to their overuse, 
misuse and to the lack of development of new effective drugs by the pharmaceutical 
industry [96]. This growing incidence of multi-drug resistant pathogenic microorganisms 
leads to the urgent need of searching for new antimicrobial compounds [97]. Marine 
actinobacteria have proved to produce numerous secondary metabolites with 
antimicrobial activity (Table 1). Some relevant examples illustrated in the literature 
include compounds with activity against Gram-positive pathogenic bacterial strains, such 
as abyssomycin C, a polycyclic polyethylene produced by an actinobacteria belonging 
to the genus Verrucosispora exhibiting antibacterial activity against methicillin-resistant 
Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis [98, 99] or tirandamycin 
C, a dienoyl tetramic acid produced by a marine Streptomyces with activity against 
vancomycin-resistant Enterococcus faecalis (VRE) [93]. Other examples include 
compounds with a broader spectrum of action, being effective against both Gram-
positive and Gram-negative strains, such as essramycin, a pyrimidine produced by a 
marine strain of Streptomyces effective against Escherichia coli, Pseudomonas 
aeruginosa, Bacillus subtilis, Staphylococcus aureus and Micrococcus luteus [51] or 
bonactin, an ester also produced by a marine strain of Streptomyces with activity against 
Bacillus megaterium, Micrococcus luteus, Kleibsiella pneumoniea, Staphylococcus 
aureus, Alicagenes faecalis and Escherichia coli [38]. There are also some compounds 
described with antifungal activity, as saadamycin, a polyketide produced by an 
endophyte marine Streptomyces [80] or chandrananimycin, a phenoxazin-3-one produced 
by a marine strain of Actinomadura with activity against Candida albicans [43]. 
Considering the numerous antimicrobial compounds produced by marine actinobacteria, 
these bacteria constitute a hotspot for the screening of novel compounds capable of 
responding to the urgent problem of antibiotic-resistant strains.  
 
3.2. Anticancer Activity 
 
Cancer is one of the most significant public health problems in the world, being one 
of the main causes of human death [100]. The pursuit of compounds exhibiting novel 
anticancer activities and/or that may be more effective while causing less negative 
effects on healthy cells is one of the major focuses of current scientific research [101]. In 
this field, marine actinobacteria are also rising to prominence and numerous compounds 
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synthesized by these organisms have been described to hold activity against cancer 
cells (Table 1). One of the best examples of success is salinosporamide A. This 
compound is a rare bicyclic γ-lactam-β-lactone isolated from the marine actinobacteria 
Salinispora tropica. Salinosporamide A revealed an inhibitory effect in several malignant 
cell types and has entered in clinical trials for the treatment of lymphoma, solid tumors, 
and multiple myeloma [14]. Another example of a relevant anticancer compound produced 
by a marine actinobacteria is streptoanthraquinone A, a polycyclic quinone obtained from 
a marine Streptomyces which induces apoptosis in glioma cells and suppresses the 
proliferation of four different glioma cell lines [70]. Considering the high potential of marine 
actinobacteria to produce anticancer compounds, bioprospection of these 
microorganisms in unexplored marine habitats offers very promising results.  
 
4. Actinobacteria in Kelps 
 
Kelps are large brown marine algae that belong to the class Phaeophyceae and to 
the order Laminariales. These algae usually form complex structures, known as kelp 
forests, which dominate shallow rocky coasts of cold-water marine habitats distributed 
worldwide, including the north coast of Portugal. Countless organisms live in association 
with these kelp forests such as marine mammals, fishes, crabs, sea urchins, molluscs 
and other algae, making this one of the most diverse and productive ecosystems of the 
world [102]. Kelps are a rich source of bioactive compounds that include polysaccharides, 
peptides, omega‐3 fatty acids, carotenoids, phenolics and vitamins [103]. Many of these 
molecules have a relevant role in the most varied sectors, such as in the pharmaceutical, 
agricultural, nutritional and cosmetic industries [104-106].  
Macroalgae, including kelps, are known to host diverse species of actinobacteria, both 
epiphytic and endophytic, but very few studies have been carried out to assess their 
biotechnological potential, with the majority of the bioactivity screenings targeting 
epiphytic microorganisms, mainly fungi [107]. Nevertheless, some studies demonstrated 
that actinobacteria isolated from macroalgae are capable of producing diverse bioactive 
compounds, including antibiotics and antitumor and anti-inflammatory compounds [108, 
109]. Focusing in the endophytic microorganisms, these are characterized by living in the 
inner tissues of a plant/algae without causing negative damages to the host [110]. During 
this symbiotic association, endophytes produce secondary metabolites that improve the 
fitness of the host plant/algae and its resistance against environmental stressors, 
obtaining in return nutrients and shelter from their host [111]. The interaction between 
endophytic microorganisms and their host may result in the production of secondary 
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metabolites with relevant bioactivities [112]. Considering the many bioactive properties of 
kelp extracts, known and well established for years, one possibility that remains open is 
the fact that the production of these metabolites can be driven by the community of 
actinobacteria present in the macroalgae. 
Thus, the bioprospection of endophytic actinobacteria in the kelp L. ochroleuca is an 
innovative study that may contribute to the discovery of novel compounds with 
pharmacological, industrial or ecological interest.  
 
5.  Aim and outline of this thesis 
 
Novel drugs are urgently needed to tackle serious illnesses that affect millions of 
people worldwide, such as cancer pathologies or infections caused by antibiotic-resistant 
microorganisms. Secondary metabolites produced by marine actinobacteria constitute a 
promising solution for these alarming problems, due to their clinical relevant properties. 
In this context, the present master’s thesis aimed to explore the diversity and potential 
of actinobacterial endophytes of the macroalgae L. ochroleuca to produce secondary 
metabolites with antimicrobial and anticancer activities. The study had as starting point 
a collection of 112 microbial strains isolated by the student during a work conducted in 
the last year of her BSc degree.  
This thesis is organised in five sections. It starts with an Introduction where the main 
characteristics of the phylum Actinobacteria, with special emphasis on marine 
actinobacteria, and their recognized value as producers of antimicrobial and anticancer 
compounds are addressed. This section is followed by the Materials and Methods where 
the whole methodology associated to the work performed is detailed, namely the 
methodology employed for the taxonomic identification of the isolated microorganisms, 
the bioactivity assays and chemical elucidation of bioactive compounds. The subsequent 
two sections are relative to the Results and to the Discussion, where the results obtained 
under the scope of this thesis are presented and discussed. Finally, the last section 
consists on the main conclusions of the performed work. 
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II. Materials and Methods 
 
 
As mentioned in the previous section, this work had as starting point a collection of 112 
microbial strains isolated from L. ochroleuca in a study conducted by the student during 
the last year of her BSc degree. Though no actinobacterial strains were isolated in the 
scope of present thesis, the methodology employed in the previous BSc study to achieve 
this goal will be here referred in order to allow a better understanding of the whole work 
performed. 
 
1. Sampling and Bacterial Isolation 
 
Samples of L. ochroleuca were collected in the intertidal zone of Mindelo rocky shore, 
located in northern Portugal (41.309298°; -8.742228°), transported to the laboratory 
under refrigeration and processed on the same day. The collected specimens were 
washed with sterile sea water and segmented into three distinct parts: holdfast, stipe and 
blade (Fig. 2). Each part was cut into small pieces (ca. 2 cm in length) that were subjected 
to a chemical and enzymatic disinfection treatment for the elimination of the epiphytic 
microbial community. In this process, samples were incubated in a CTAB buffer solution 
(diluted 1:100) containing proteinase K (20 mg/mL) for 30 min at 60 °C, and washed for 
three consecutive times with sterile sea water for 1 min [113]. The effectiveness of the 
disinfection treatment was evaluated by plating the final wash water and the disinfected 
tissues of each part of the algae on Plate Count Agar (PCA). To increase the isolation of 
endophytic actinobacteria, grinded tissues from the different parts of L. ochroleuca were 
inoculated in duplicate in three selective culture media: Starch-Casein-Nitrate agar 
(SCN: 10 g of soluble starch, 0.3 g of casein, 2 g of K2HPO4, 2 g of KNO3, 2 g of NaCl, 
0.05 g of MgSO4.7H2O, 0.02 g of CaCO3, 0.01 g of FeSO4.7H20 and 17 g of agar, per 
litre of distilled water), Raffinose-Histidine agar (RH: 10 g of raffinose, 1 g of L-Histidine, 
1 g of K2HPO4, 0.5 g of MgSO4.7H2O, 0.01 g of FeSO4.7H20 and 17 g of agar, per litre 
of distilled water) and Nutrient-Poor Sediment Extract agar (NPS: 100 mL of marine 
sediment extract obtained by washing 900 mL of sediments with 500 mL of seawater 
and 17 g of agar, per litre of seawater). All culture media were supplemented with 
cycloheximide (50 mg/L) and nalidixic acid (50 mg/L) to inhibit the growth of fungi and 
Gram-negative bacteria. The plates were incubated at 28 °C for a period of up to 6 
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weeks. Morphologically distinct colonies were isolated and cryopreserved at -80 ºC in 
30% (v/v) of glycerol. 
 
Figure 2. Specimen of L. ochroleuca with the indication of (A) blade, (B) stipe and (C) holdfast. 
 
 
2. Taxonomic Identification of the Isolates 
 
All isolates were taxonomically identified through 16S rRNA gene sequencing. For 
each isolate, genomic DNA was extracted using the E.Z.N.A. Bacterial DNA Kit (Omega 
Biotek, Norcross, GA) according to the manufacturer's recommendation. The 16S rRNA 
gene was amplified by PCR using the universal primers 27F (5'-
GAGTTTGATCCTGGCTCAG-3') and 1492R (5'-TACGGYTACCTTGTTACGACTT-3') 
[114, 115]. The PCR mixture (final volume of 10 μL) consisted in: 5 μL of Qiagen Multiplex 
PCR Master Mix (Qiagen, Valencia, CA), 1 μL of each primer (2 µM), 2 μL of DNA 
template and 1 μL of nuclease-free water. The reaction was started with an initial 
denaturation at 95 °C for 15 min followed by 30 cycles of denaturation at 94 °C for 30 s, 
annealing at 48 °C for 90 s and extension at 72 °C for 90 s, and a final extension at 72 
°C for 10 min. PCR products were separated on a 1.4% agarose gel containing SYBR 
Safe (ThermoFisher Scientific, USA). Purification and sequencing of the samples was 
performed by GenCore, I3S (Instituto de Investigação e Inovação em Saúde, Portugal) 
as follows: 10 µL reactions were prepared by combining 0.8 µL of Big Dye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Life Technologies, United Kingdom) 
with 0.8 µL of 10 µM primers (the same primers used in the PCR), 1 mL of BigDye 
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Terminator v1.1 & v3.15X Sequencing Buffer and water DNase, RNase-free (Gibco, 
USA). Thermal cycler conditions were: 96 °C for 2 min, 35 cycles at 96 °C for 30 s, 50 
°C for 15 s and 60 °C for 4 min and one final hold at 60 °C for 10 min. Sequencing 
reaction products were purified using Sephadex™G-50 Fine DNA Grade columns (GE 
Healthcare, United Kingdom) according to the manufacturer’s recommendations. 
Purified samples were added to 12 µL Hi-Di™ formamide (Life Technologies, USA). 
Sequencing was performed in a Genetic Analyzer 3130xl sequencer (Applied 
Biosystems), according to the manufacturer’s recommendations. The obtained 16S 
rDNA sequences were analysed using the Geneious software, version 11.1.4. The 
taxonomic affiliation of the isolates was established using the 16S ribosomal RNA 
(Bacteria and Archaea) database from NCBI BLAST tool 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) and confirmed using the Identify tool from 
EzTaxon (http://www.ezbiocloud.net/) and the Sequence Match tool from the Ribosomal 
Database Project (https://rdp.cme.msu.edu/index.jsp). To complement the taxonomic 
evaluation of the isolates, a phylogenetic tree was elaborated. According to BLAST 
results, the 3 closest neighbour sequences for each isolate were selected, choosing only 
organisms belonging to different species. Once the sequences were obtained for all 
isolates (128 sequences), a Geneious alignment was performed resulting in an alignment 
with 1281 bp. The phylogenic tree was made using the Maximum Likelihood method with 
1000 bootstraps based on the Tamura-Nei model. Strains KENR90, KENR91 and 
KENR92 were not included in the tree since their nucleotide sequences were too short 
(590 bp, 617 bp and 833 bp, respectively). The tree was constructed using the Molecular 
Evolutionary Genetics Analysis program Version 7.0 (MEGA7) [116]. 
 
3. Bioactivity Assays 
 
3.1. Preparation of Crude Extracts 
Each actinobacterial isolate was grown in a 100 mL Erlenmeyer flask containing 30 
mL of liquid culture medium with a composition identical to the solid medium from which 
the isolate was obtained (without the addition of cycloheximide and nalidixic acid) (Fig. 
3A). The flasks were incubated at 28 ºC, 100 rpm, in the dark. After four days of 
incubation, 0.5 g of Amberlite XAD16N resin (Sigma-Aldrich, St. Louis, Mo.) were added 
to the culture medium and the flasks were incubated for another three days (Fig. 3B). 
The obtained biomass and resin were then harvested by centrifugation (4.600 rpm for 10 
min), freeze-dried and preserved at -20 ºC. Each culture was extracted using 30 mL of a 
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solution of acetone/methanol 1:1 (v/v) and the organic layer was dried in a rotary 
evaporator. The resulting crude extract (Fig. 3C) was dissolved in dimethyl sulfoxide (≥ 
99.9%, DMSO, Sigma-Aldrich, USA) to obtain stock solutions at 10 mg/mL, 3 mg/mL and 
1 mg/mL for the bioactivity assays.   
 
Figure 3. Liquid cultures of some actinobacterial isolates (A) bacterial growth in the Erlenmeyer 
flasks, (B) Amberlite XAD16N resin added to the cultures and (C) crude extracts obtained from some 
liquid cultures. 
 
3.2. Screening of Antimicrobial Activity 
The antimicrobial activity of the crude extracts obtained from the actinobacterial 
isolates was tested against five reference microorganisms - Escherichia coli (ATCC 
25922), Bacillus subtilis (ATCC 6633), Staphylococcus aureus (ATCC 29213), 
Salmonella typhimurium (ATCC 25241) and Candida albicans (ATCC 10231) - using the 
agar-based disk diffusion method (Fig. 4). The bacterial strains were grown in Mueller-
Hinton agar (MH) and C. albicans in Sabouraud Dextrose agar (SD). For the bioassay, 
reference microorganisms were suspended in the corresponding liquid medium and their 
turbidity was adjusted to 0.5 McFarland standard (OD625 = 0.08−0.13). The suspensions 
were then used to inoculate agar plates (MH or SD, according to the reference 
microorganism) by evenly streaking the plates with a swab dipped in the suspension. 
Blank paper disks (6mm in diameter; Oxoid) were placed on the surface of the inoculated 
medium and 15 μL of each actinobacterial crude extract (10 mg/mL) were loaded into 
the disks. Positive control consisted in 15 μL of enrofloxacin (10 mg/mL) for the bacterial 
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strains, and 15 μL of nystatin (10 mg/mL) for C. Albicans, and the negative control 
consisted in 15 μL of DMSO. Antimicrobial activity was determined by measuring the 
diameter of the inhibition halo formed around each disk after 24 h of incubation at 37 °C. 
For each extract, assays were conducted in duplicate against each reference 
microorganism. For extracts exhibiting antimicrobial activity, the minimal inhibitory 
concentration (MIC) (Fig. 5) was also determined. Inoculum suspensions of the reference 
strains were prepared as mentioned above. For each extract, stock solutions at 1 mg/mL 
were prepared in the appropriate culture medium. Two-fold dilutions in the same medium 
were sequentially obtained from these stocks, resulting in extracts solutions with 
concentrations ranging from 1 mg/mL to 0.487 µg/mL. The assay was conducted in 96 
well plates by adding 50 μL of the microbial inoculum (diluted 1:100) and 50 μL of each 
extract dilution to each well, in triplicate for each extract dilution. The MIC was 
determined by spectrophotometric analysis (625 nm), after 18 h of incubation at 37 °C. 
The growth control consisted in 50 μL of microbial inoculum and 50 μL of medium broth 
and the sterility control in 100 μL of medium broth. For each extract, MIC was determined 
from two independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Illustrative diagram of the agar-based disk diffusion assay. 
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Figure 5. Illustrative diagram of the minimal inhibitory concentration (MIC) assay.  
PC and NC indicate positive and negative controls, respectively. 
 
 
3.3. Screening of Anticancer Activity 
The anticancer activity of each actinobacterial crude extract was tested in two human 
cancer cell lines - breast ductal carcinoma (T-47D) and neuroblastoma (SH-SY5Y) 
(Sigma-Aldrich, St. Louis, Missouri, USA) - using the MTT assay (Fig. 6). T-47D cells 
were grown in Dulbeco's Modified Eagle Medium (DMEM) (Gibco, Thermo Fischer 
Scientific, Waltham, Massachusetts, USA) and SH-SY5Y in a 1:1 mixture of MEM/F12 
medium, both supplemented with 10% (v/v) fetal bovine serum (Biochrom, Berlin, 
Germany), 1% (v/v) antibiotics (100 mg/L streptomycin), 100 IU/mL penicillin (Biochrom, 
Berlin, Germany) and 0.1% (v/v) amphotericin (GE Healthcare, Little Chafont, United 
Kingdom), at 37 °C in an incubator with 5% carbon dioxide. The cells were seeded in 96-
well plates at 6.6×104 cells/mL, let to adhere overnight and exposed to the extracts (15 
µg/mL) for 24 and 48 h. Positive control consisted in 20% DMSO and solvent control in 
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0.5% DMSO. After 24 and 48 h of exposure, 20 μL of MTT (final concentration: 0.2 
mg/mL) were added per well and the plates were incubated for an additional period of 4 
h at 37 °C. After this step, the culture medium was removed from each well and 100 μL 
of DMSO were added to the wells. The results were obtained by reading the OD of the 
plates at 570 nm in a plate reader (Biotek, Synergy HT). The assays were performed in 
triplicate and two independent experiments were performed for each extract. Cellular 
viability was expressed as a percentage relative to the solvent control. Extracts exhibiting 
anticancer activity were additionally tested on a non-tumour cell line, human brain 
capillary endothelial cells (hCMEC/D3) (kindly donated by Dr. P. O. Courad (INSERM, 
France) following the same procedure described above. 
 
Figure 6. Illustrative diagram of the MTT assay. 
 
 
4. Dereplication of Active Crude Extracts 
 
A set of 35 actinobacterial crude extracts was selected for dereplication analysis. The 
selection of these extracts was made according to their performance in the bioactivity 
screenings: inhibition halos > 1 cm and capability to decrease at least one cancer cell 
line viability to less than 30% (Annex 1). The selection also took into account the 
phylogenetic relationship of the actinobacterial isolates producing the bioactive extracts, 
which was evaluated through the construction of a phylogenetic tree (Annex 2). From 
this analysis, seven strains (KENR16B, KENR19, KENR21, KENR34, KENR69, 
KENR79 and KENR93) were discarded once they proved to be highly similar to others, 
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both in terms of bioactive profile and taxonomic classification. The crude extract of each 
selected isolate was analysed by Liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). The samples were prepared in 1.5 mL vials at 1 mg/mL. The eluents used 
were water/methanol/formic acid 95:5:0.1 (v/v) and acetone/methanol/formic acid. 
95:5:0.1 (v/v). The separation was carried out on an ACE UltraCore 2.5 Super C18 (75 
× 2.1 mm) column. The obtained data were processed using the dereplication workflow 
from Global Natural Product Social Molecular Networking (GNPS) 
(https://gnps.ucsd.edu/) [117] using the default parameters, except for the ion mass 
tolerance precursor which was set at 0.01 Da and fragment ion mass tolerance which 
was set at 0.04 Da. All compounds that fulfilled the following conditions were considered 
as likely identities: natural compounds with relevant biological activity (i.e., antimicrobial, 
anticancer, cytotoxic) and cosine value > 0.85. The dereplication data was matched with 
the strain’s bioactivity profiles, allowing ultimately to select which strains would be more 
promising to proceed to a bioactivity-guided isolation of novel bioactive compounds.  
 
5. Bioactivity-Guided Study of Bioactive Molecules - 
Streptomyces sp. KENR25 
 
The strategy employed within the present topic corresponds to part of a traditional 
natural product discovery pipeline relying on the combination of fractionation techniques 
and submission of the resulting fractions to bioassays (Fig. 7). The fractionation 
techniques are based on chromatographic procedures which allow the separation, based 
on selected physical parameters, of different components present in a sample. Strain 
KENR25, identified as Streptomyces sp., was selected due to its performance in the 
bioactivity screenings: both antimicrobial and cytotoxic activity against the two cancer 
cell lines tested. This selection was made before the dereplication procedure, therefore 
the composition of the crude extract and presence of known bioactive compounds was 
not yet known. 
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Figure 7. Diagram of the bioassay-guided workflow to study bioactive molecules. 
 
5.1.     Large-Scale Cultivation  
The cultivation was performed following the previously described procedure for 
growing actinobacterial isolates in liquid culture by scaling-up the culture volume. The 
strain was grown at 28 ºC, 100 rpm and in the dark, in a total of 15 L, using 1 L 
Erlenmeyer flasks, each containing 500 mL of SCN liquid medium. After four days of 
incubation, 8.3 g of resin were added to each flask and the flasks incubated for three 
additional days. The obtained biomass and resin were then harvested by centrifugation 
(4.600 rpm for 10 min), freeze-dried and preserved at -20 ºC until organic extraction and 
further fractionation. 
 
5.2.     Organic Extraction 
The extraction apparatus was prepared by assembling a Büchner funnel containing 
two Whatman grade 1 filter paper (Whatman, Sigma-Aldrich, USA) and a cloth, a vacuum 
adapter and a round bottom (RB) flask. The freeze-dried biomass and the resin obtained 
from large-scale cultivation were firstly placed in a stainless-steel goblet and macerated 
with a spatula. Then, the biomass and resin were entirely immersed in a solution of 500 
mL of acetone/methanol 1:1 (v/v). This mixture was left under constant stirring for 2 h, at 
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30 °C. The ensuing steps consisted in decanting the solvent content into the Büchner 
funnel, collect the extract in the RB flask and recover into the goblet the biomass that 
was retained in the cloth. This process was repeated, adapting the solvent mixture and 
stir time, until the solvent content run out of colour. After the extraction was complete, 
the RB flask was removed from the assembly and the solvents dried in a rotary 
evaporator. The content of the RB flask was dissolved using acetone and methanol and 
filtered through cotton to retain any remaining cells. The filtered extract was finally dried 
under vacuum to evaluate the obtained mass of the crude extract.  
 
5.3.     Bioassay-guided fractionation 
5.3.1.     Vacuum Liquid Chromatography (VLC) 
The crude extract was fractionated by normal phase Vacuum Liquid Chromatography 
(VLC) (Fig. 8) using a solvent polarity gradient (Table 2) on a glass fritted 
chromatography column. A thin layer of sand (ca. 1 cm in height) and 300 g of silica gel 
60 (0.015-0.040 mm) (Merck, Sigma-Aldrich, USA) were placed in the column and then 
a mixture of hexane/ethyl acetate 9:1 (v/v) was used to pack the column. The crude 
extract was dissolved using a mixture of hexane/ethyl acetate 9:1 (v/v) and gently loaded 
onto the top of the silica column. A second layer of sand was positioned over the extract. 
The different eluents were sequentially added to the column without letting the silica 
surface become exposed to air. A total of ten fractions (A-I2, in order of increasing 
polarity) were collected in RB flasks and dried in a rotary evaporator. The 
chromatographic fractions were resuspended using dichloromethane and ethyl acetate 
1:1 (v/v) (A-E) or methanol (F-I2), filtered through cotton, transferred to pre-weighted 16 
mL vials and dried under vacuum. The mass of each fraction was determined, and the 
vials stored at -80 ºC until further use. The antimicrobial and anticancer activity of the ten 
VLC fractions was tested following the same protocols previously described for these 
assays. To gather information on the structure of the potentially active compounds, each 
active fraction, as well as its adjacent ones, was analysed by proton nuclear magnetic 
resonance (1H NMR) spectroscopy. Each sample was prepared by dissolving the mass 
in a deuterated solvent methanol or chloroform, according to their polarity, and 
transferred into 400MHz NMR tubes (Norell Standard SeriesTM 5 mm, Sigma-Aldrich, 
USA). The samples were then sent to the Laboratory for Structural Elucidation (LAE) of 
the Materials Centre of the University of Porto (CMUP) where a Resonance 
Spectrometer Bruker Avance III 400 MHz, 9.4 Tesla was used for the analysis. The data 
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was analysed using the Mnova software allowing to verify the fractions spectra similarity. 
At this point it was decided to focus attention on the antimicrobial activity of four fractions 
- D, E, F and G - that proved to be active against C. albicans. Considering the antibiogram 
results, together with the 1H NMR spectra similarity, these four fractions were dissolved 
using dichloromethane, pooled together in the same vial and processed as a single 
fraction (DEFG). 
 
Table 2. Solvent mixtures used for elution of Streptomyces sp. KENR25 crude extract on 
Vacuum Liquid Chromatography. Due to the high polarity of the extract, the last solvent mixture 
was repeated (fraction I2) 
 
Fraction Solvent Mixtures Volume 
   
A 10% EtOAc - 90% Hex > 500mL 
B 30% EtOAc - 70% Hex 500 mL 
C 50% EtOAc - 50% Hex 500 mL 
D 75% EtOAc - 25% Hex 500 mL 
E 100% EtOAc  500 mL 
F 10% MeOH - 90% EtOAc  500 mL 
G 30% MeOH - 70% EtOAc 500 mL 
H 60% MeOH - 40% EtOAc 500 mL 
I 100% MeOH  500 mL 
I2 100% MeOH 500 mL 
   
 
Figure 8. Vacuum Liquid Chromatography fractionation of Streptomyces 
sp. KENR25 crude extract. 
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5.3.2.     Flash Chromatography (FC) 
 
The antimicrobial-active DEFG fraction was fractionated using normal phase Flash 
Chromatography (FC). A Thin-Layer Chromatography (TLC) (Fig. 9A) was initially 
performed as a polarity indicator for the compounds present in the DEFG fraction, 
allowing determining the appropriate first solvent mixture to initiate the FC (Fig. 9B). For 
the TLC procedure, the fraction was applied onto a silica gel plate using a glass capillary 
and a mixture of ethyl acetate/hexane 1:1 (v/v) was used as mobile phase. To allow the 
detection of the compounds, the plate was stained using phosphomolybdic acid (PMA) 
and heated to activate the stain for visualization. The active DEFG fraction was further 
fractionated by normal phase FC. According to the TLC results it was decided that the 
first elution solvent mixture for FC would be ethyl acetate/hexane 2:3 (v/v). This mixture 
was used to solvate the silica gel (0.040-0.063 mm) in the column. The sample was 
added to the top of the silica layer, followed by the addition of cotton to protect the silica 
surface from the impact of solvents addition. Elution was performed using a gradient of 
increasing polarity (Table 3) and the sample was recovered in 10 mL tubes. Tubes with 
a similar sample coloration and profile on the TLC plates were combined in separated 
RB flasks, leading to a total of nine sub-fractions (DEFG-A - DEFG-I). These sub-
fractions were transferred to 8 mL pre-weighted vials and dried under vacuum. The mass 
of each sub-fraction was determined, and the vials stored at -20 ºC. To identify the 
fraction containing the active compounds responsible for the activity against C. albicans, 
the nine FC fractions were tested following the same protocol previously described for 
the antimicrobial assay, and the active fractions were also analyzed by 1H NMR. 
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Table 3. Solvent mixtures used for elution of the DEFG fraction on FC 
 
Solvent Mixtures Volume 
  
60% Hex - 40% EtOAc 500 mL 
50% Hex - 50% EtOAc 100 mL 
40% Hex - 60% EtOAc 50 mL 
30% Hex - 70% EtOAc 50 mL 
20% Hex - 80% EtOAc 50 mL 
10% Hex - 90% EtOAc 50 mL 
100% EtOAc 50 mL 
90% EtOAc: - 10% MeOH 50 mL 
80% EtOAc - 20% MeOH 50 mL 
60% EtOAc - 40% MeOH 50 mL 
70% EtOAc - 30% MeOH 50 mL 
100% MeOH 100 mL 
 
 
 
 
 
 
 
 
 
 
Figure 9. Sub-fractioning of the DEFG fraction. (A) pre-chromatography 
Thin-Layer Chromatography and (B) Flash Chromatography column. 
 
5.3.3.     High-Performance Liquid Chromatography (HPLC) 
The data obtained with all the procedures described above for the active fractions, 
the higher amount of available extract and the chromatogram simplicity of the sample, 
led to the selection of the fraction DEFG-A for semi-preparative High Performance Liquid 
Chromatography (HPLC) fractionation in a Waters Alliance HPLC combined with a 
Photodiode Array (PDA) detector. The sample was first dissolved in approximately 5 mL, 
using dichloromethane and methanol, and filtered through cotton into a vial. In each run, 
a sample volume of 250 μL was injected and the separation was carried out on a Luna 
10u C18 column (100A, 4 μm, 250 × 10 mm, Phenomenex), with a flow rate of 3 mL/min. 
The chromatogram was monitored with fixed wavelengths at 225 nm and 254 nm. The 
elution was performed using HPLC grade acetonitrile and ultra-pure water according to 
A B 
FCUP 
Endophytic Actinobacteria from Laminaria ochroleuca: a new source of bioactive compounds 
24 
 
the following program: acetonitrile/water 3:7 (v/v) for 40 min followed by a linear gradient 
to 95% acetonitrile, held for 15 min before returning to the initial conditions. The 10 HPLC 
fractions were transferred to 8 mL pre-weighted vials and dried under vacuum. The mass 
of each fraction was determined, and the vials stored at -20 ºC. 
 
5.4. Molecular Networking 
A molecular networking was performed as an additional approach to study the 
metabolomic profile of DEFG sub-fractions that showed positive result in the 
antimicrobial assay. The first step was to analyse the selected fractions by LC-MS/MS, 
following the same protocol previously described for this technique. The obtained data 
followed then the “Data analysis” workflow from GNPS using the default parameters, 
except for the ion mass tolerance precursor which was set at 0.01 Da and fragment ion 
mass tolerance which was set at 0.04 Da. The GNPS tools were used to get an overview 
of identified compounds/clusters and then the MS/MS data was downloaded to 
Cytoscape software, version 3.6.1., where the molecular networking was generated 
(http://www.cytoscape.org/). A colour layout was applied to the network to allow an easier 
visualization and interpretation of the results.  
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III. Results 
 
 
1. Phylogenetic Identification of Actinobacteria Isolated from 
L. ochroleuca 
 
At the beginning of the present MSc project, a total of 112 bacterial strains were 
available for the study, being 90 identified as actinobacteria (and the remaining identified 
as Firmicutes, Proteobacteria and Fungi). These actinobacteria were previously isolated 
from disinfected tissue fragments obtained from holdfasts, stipes and blades of L. 
ochroleuca. Most of the strains (89%) were isolated from the holdfasts (Fig. 10A). The 
highest percentage of the isolates was recovered from the medium SCN (63%), followed 
by RH (27%) and NPS (10%) (Fig. 10B). The isolates exhibited diverse morphological 
features, with several strains presenting characteristics typical of actinobacteria, such as 
slow growth, formation of hyphae and production of spores and pigments, the latter 
sometimes leading to the change of the colour of the culture medium (Fig. 11). 
 
 
Figure 10. Actinobacterial isolates recovered from L. ochroleuca. (A) Percentage of actinobacterial strains isolated 
from holdfasts, stipes and blades of L. ochroleuca and (B) Distribution of the isolates by the selective culture media 
used in the study (SCN: Starch-Casein-Nitrate agar; RH: Raffinose-Histidine; NPS: Nutrient-Poor Sediment). 
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Figure 11. Morphological diversity of some actinobacterial strains isolated from L. ochroleuca: (A) strain KENS1, (B) strain 
KENR91, (C) strain KENR92, (D) strain KENR94, (E) strain KENRB10, (F) strain KENR56, (G) strain KENR81 and (H) 
strain KENB8. 
 
The disinfection treatment was not entirely effective, as five isolates were recovered 
from the disinfection controls. Two of these isolates were grown in a PCA plate 
inoculated with a sterilised holdfast fragment being identified as  Pseudomonas sp. and 
Lysinibacillus sp., two were obtained in a PCA plate inoculated with the final wash water 
from the disinfection of a holdfast fragment being identified as Bacillus sp. and 
Staphylococcus sp., and one was found in a PCA plate inoculated with the final wash 
water from the disinfection of a blade fragment being identified as a Penicillium sp. 
Most actinobacterial isolates identified by 16S rRNA gene sequencing belonged to 
the Streptomyces genus. However, strains belonging to other genera (including some 
rare) were also retrieved: Isoptericola, Rhodococcus, Nonomuraeae, Nocardiopsis, 
Microbispora and Microbacterium (Figs. 12A and 13). All of these genera, except for 
Microbispora, were found in holdfasts of L. ochroleuca, while only two actinobacterial 
genera were recovered from stipes (Microbispora and Microbacterium) and blades 
(Streptomyces and Microbacterium) (Fig. 12B). The selective medium SCN allowed the 
retrieval of strains belonging to all genera identified in this study, revealing to be the most 
efficient medium (Fig. 12C). Growth of Streptomyces and Microbacterium strains was 
observed in all culture media used. Several of the isolated strains, many of them affiliated 
with the genus Streptomyces, were found to group very closely with high bootstrap 
values (Fig. 13), indicating a high similarity between them. In addition, the obtained 
isolates consistently clustered with species already described in the literature, discarding 
the possibility of some of these isolates constitute a new species (Fig. 13). 
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Figure 12. Actinobacterial genera recovered from L. ochroleuca. (A) Percentage of actinobacterial genera 
isolated from L. ochroleuca, (B) genera distribution in the holdfast, stipe and blade of the macroalgae and 
(C) genera distribution according to the selective culture media used for the isolation.   
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Figure 13. Phylogenetic relationship of the 87 actinobacterial isolates recovered from L. ochroleuca, based on 16S rRNA 
gene homology with their GenBank nearest neighbours. Numbers at nodes represent bootstrap values when higher than 
60%. Numbers in parenthesis correspond to GenBank accession numbers. Bacillus subtilis was used as outgroup.  
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2. Bioactive Potential of the Actinobacterial Isolates 
 
Antimicrobial assays identified 45 isolates (half of the total number of the 
actinobacterial strains isolated) capable of inhibiting the growth of C. albicans or S. 
aureus. These isolates were affiliated with the genera Streptomyces (39 strains), 
Isoptericola (one strain), Nonomuraeae (one strain), Nocardiopsis (one strain), 
Microbispora (one strain) and Microbacterium (two strains). From these 45 isolates, 37 
exhibited activity against C. albicans, three showed activity against S. aureus and five 
had activity against both microorganisms (Table 4). The inhibition halos observed had a 
diameter that varied between 7 and 25 mm, and all of them presented a translucent 
appearance (Fig. 14). MIC values determined for the actinobacterial extracts ranged 
between < 0.487 and 1000 µg/mL (Table 4). The lowest MIC value attained against S. 
aureus (3.9 µg/mL) was observed for extracts of the Streptomyces strains KENR60 and 
KENR64, isolated from holdfasts of L. ochroleuca. The lowest MIC value attained against 
C. albicans (< 0.487 µg/mL) was observed for crude extract of the Streptomyces 
KENR25, also isolated from holdfasts of L. ochroleuca. Although most of the isolates 
exhibiting antimicrobial activity were recovered from holdfasts (89%), some of them were 
also obtained from blades (9%) and stipes (2%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Antimicrobial activity of actinobacterial strains isolated from L. ochroleuca. (A-E) 
Examples of inhibition halos against C. albicans and (F-G) against S. aureus. (A) Strain 
KENR13A, (B) strain KENR25, (C) strain KENR6, (D) strain KENR16B, (E) strain KENR21, (F) 
strain KENR64 and (G) strain KENR60. 
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Table 4. Actinobacteria isolated from L. ochroleuca with antimicrobial activity. The diameter of inhibition halos obtained 
by the agar disk diffusion method and MIC values are shown 
 
  Diameter of Inhibition Halos MIC (µg/mL) 
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KENR3 Streptomyces olivochromogenes            31.25 
KENR6 Streptomyces sp.           1000 0.975 
KENR8 Streptomyces atratus            1.95 
KENR11A Streptomyces sp.            7.81 
KENR13 Streptomyces sp.            1.95 
KENR13A Streptomyces sp.            0.975 
KENR13B Streptomyces sp.           1000 7.81 
KENR14 Streptomyces iamenensis            7.81 
KENR16B Streptomyces sp.            15.62 
KENR17A Streptomyces sp.           500 1.95 
KENR18 Streptomyces sp.           1000 0.975 
KENR19 Streptomyces sp.            0.975 
KENR21 Streptomyces sp.            1.95 
KENR21A Streptomyces sp.            0.975 
KENR24 Streptomyces sp.            7.81 
KENR25 Streptomyces sp.            < 0.487 
KENR29 Nonomuraea sp.            3.9 
KENR31 Streptomyces sp.           62.5 1000 
KENR33 Streptomyces lannensis            1.95 
KENR34 Streptomyces sp.            15.62 
KENR35 Streptomyces sp.            0.975 
KENR36 Streptomyces sp.            125 
KENR42 Streptomyces mirabilis            125 
KENR49 Streptomyces atratus            3.9 
KENR60 Streptomyces sp.           3.9  
KENR64 Streptomyces sp.           3.9  
KENR65 Streptomyces sp.            125 
KENR69 Streptomyces sp.            15.62 
KENR70 Nocardiopsis prasina            15.62 
KENR72 Streptomyces aureus            1.95 
KENR74 Streptomyces sp.            1.95 
KENR77 Streptomyces sp.            < 0.487 
KENR79 Streptomyces sp.            0.975 
KENR80 Streptomyces sp.            15.62 
KENR81 Streptomyces sp.            3.9 
KENR84 Isoptericola sp.            3.9 
KENR86 Streptomyces sp.            500 
KENR91 Streptomyces sp.            7.81 
KENR93 Microbacterium testaceum            7.81 
KENR94 Streptomyces sp.           7.81  
KENB3 Streptomyces sp.            7.81 
KENB8 Streptomyces sp.            500 
KENB9 Streptomyces sp.            3.9 
KENB10 Microbacterium testaceum           1000 250 
KENS2 Microbispora bryophytorum            1.95 
   
No 
Halo 
< 1 
cm 
1 - 2 
cm 
> 2 
cm   
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The screening for anticancer activities revealed 30 isolates that had cytotoxic activity 
(i.e. reducing viability to less than 50% of the control) against at least one of the tested 
human cancer cell lines. Fifteen isolates were able to decrease the viability of SH-SY5Y 
cells to less than 50%, while two isolates produced this effect in T-47D cells and 13 
isolates had this effect in both cell lines (Fig. 15A and 15B). Strains KENR18, KENR25, 
KENR59, KENR60, KENR64, KENR65, KENR91, KENR94 and KENB1 (all 
Streptomyces) had a prominent activity against the cell line SH-5YSY, reducing its 
viability by more than 90%. Some of these strains (KENR60, KENR64, KENR65, 
KENR94 and KENB1) also caused a similar effect in the cell line T-47D. Although most 
of the extracts with high activity had effect in both cell lines, some of them were more 
effective against only one cell line. This situation was verified for the extracts from the 
Streptomyces strains KENR6, KENR23D, KENR26, KENR31, KENR35, KENR57, 
KENR71, KENR74, KENR79, KENR80, KENR81, KENR85 and KENR91, and the 
Rhodococcus strains KENR39 and KENR78, that were more effective against SH-5YSY 
cells, and of the Streptomyces strain KENR11A and Nocardiopsis KENR70, that were 
more effective against T-47D cells. Although most of the isolates with anticancer activity 
were Streptomyces, other strains also demonstrated notorious activity. For example, 
strains of the genera Rhodococcus (KENR39 and KENR78), Microbacterium (KENB10) 
and Nocardiopsis (KENR70) were also effective in decreasing the cellular viability. Once 
again, the highest percentage of strains exhibiting cytotoxic activity on cancer cells was 
retrieved from holdfasts (93%) followed by blades (7%). Effects of the crude extracts 
were also tested on a non-carcinogenic, endothelial cell line to verify their specificity 
towards cancer cells. Five extracts demonstrated high cytotoxicity on hCMEC/D3 cells, 
indicating a more general cytotoxicity. Ten extracts with cytotoxic activity on cancer cells 
caused a decrease in the viability of the non-tumour cell line less than 30% (KENR16A, 
KENR23D, KENR26, KENR31, KENR39, KENR57, KENR59, KENR71, KENR85 and 
KENB10) (Fig. 15C). In particular, extracts from the strains KENR18, KENR25, KENR59 
and KENR91 showed a promising profile with high activity on SHSY-5Y cells, but with 
low activity on normal hCMEC/D3 cells. 
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 Figure 15. Actinobacterial strains isolated from L. ochroleuca with anticancer activity. The graphs show the extracts able 
to decrease cancer cells viability to less than 50% of the control, after 24 and/or 48 h of exposure, for (A) SH5Y-SH, (B) 
T-47D, and (C) hCMEC/D3 cell lines. PC and SC indicate positive and solvent controls, respectively. Error bars represent 
standard deviation of the mean of at least duplicate assays performed in triplicates each. 
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3. Bioactive Compounds Produced by Actinobacterial Strains 
 
 According to the dereplication data, the metabolites present in most of the crude 
extracts tested are antimycins (Table 5). These compounds were present in 26 out of 
the 35 tested extracts (74%), being antimycin A2 the most common, followed by 
antimycin A3, antimycin A1 and finally antimycin A4. This latter antimycin was found only 
in the crude extract of the strain Streptomyces sp. KENR13B, with this extract being the 
only one where the presence of the 4 antimycins was detected. Antimycin was produced 
by strains of all tested genera: Streptomyces, Isoptericola, Microbispora and 
Microbacterium. For the remaining 9 extracts (26%) no match was found, according to 
the established criteria (natural compounds with relevant biological activity and cosine 
value > 0.85). In addition to antimycin, no other compound with known bioactivity was 
recorded.  
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Table 5. Dereplication results for the 35 actinobacterial crude extracts selected, indicating the compounds recorded for 
each one and the correspondent cosine value 
 
Strain Identification Compound Cosine 
    
KENR6 Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.92 
KENR8 Streptomyces atratus Antimycin A2 0.91 
KENR11A Streptomyces sp. Antimycin A2 0.93 
  Antimycin A3 0.91 
KENR13 Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.92 
KENR13A Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.92 
KENR13B Streptomyces sp. Antimycin A2 0.91 
  Antimycin A3 0.91 
  Antimycin A1 0.85 
  Antimycin A4 0.85 
KENR14 Streptomyces iamenensis Antimycin A2 0.91 
KENR17A Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.91 
KENR18 Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.92 
KENR21A Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.92 
KENR25 Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.91 
KENR29 Streptomyces sp. Antimycin A2 0.91 
  Antimycin A3 0.90 
KENR31 Streptomyces sp. No match  
KENR33 Streptomyces lannensis Antimycin A2 0.92 
  Antimycin A3 0.92 
KENR35 Streptomyces sp. Antimycin A3 0.93 
  Antimycin A2 0.92 
KENR49 Streptomyces atratus Antimycin A2 0.91 
KENR59 Streptomyces sp. No match  
KENR60 Streptomyces sp. No match  
KENR64 Streptomyces sp. No match  
KENR65 Streptomyces sp. No match  
KENR72 Streptomyces aureus Antimycin A2 0.92 
  Antimycin A3 0.90 
KENR74 Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.92 
KENR77 Streptomyces sp. Antimycin A3 0.92 
  Antimycin A2 0.90 
KENR80 Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.91 
KENR81 Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.91 
  Antimycin A1 0.85 
KENR84 Isoptericola sp. Antimycin A2 0.92 
  Antimycin A3 0.91 
  Antimycin A1 0.87 
KENR85 Streptomyces diastaticu No match  
KENR86 Streptomyces sp. No match  
KENR91 Streptomyces sp. No match  
KENR94 Streptomyces sp. Antimycin A3 0.88 
KENS2 Microbispora bryophytorum Antimycin A2 0.90 
KENB1 Streptomyces atratus No match  
KENB3 Streptomyces sp. Antimycin A2 0.92 
  Antimycin A3 0.92 
KENB9 Streptomyces sp. Antimycin A2 0.91 
KENB10 Microbacterium testaceum Antimycin A2 0.88 
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4. Bioassay-guided Study of Bioactive Molecules Produced 
by Streptomyces sp. KENR25 
 
Streptomyces sp. KENR25 was selected for further analysis based on its good 
performance in the bioactivity screenings: this strain was responsible for an inhibition 
halo of 22 mm against C. albicans and in the anticancer assay proved to be effective 
against both tested human cancer cell lines (i.e. decreased the cellular viability to less 
than 50%). To study in more detail the metabolites responsible for the bioactivity, the first 
step was to grow strain KENR25 in a larger scale to obtain enough biomass for the 
following procedures. 15 L of the strain were grown, which resulted in 45 g of biomass. 
The next step consisted in extracting the culture using methanol and acetone, yielding 
7.8 g of crude extract.  
Once the crude extract was obtained, it was fractionated by VLC. From this procedure 
10 fractions (A-I2) (Table 6) were generated and, considering the initial crude extract and 
the mass of each fraction, the yield of the procedure was approximately 85.5%. In the 
antimicrobial assay where all the fractions were tested, 5 of them - D, E, F, G and I2 – 
were able to inhibit the growth of C. albicans, with inhibition halos between 15 and 19 
mm of diameter. Fractions D, E, F and G presented more diffuse halos while fraction I2 
presented a halo with a translucent appearance (Fig. 16).  
 
Table 6. VLC fractions with the indication of the mass amount yield for each one 
Fraction Mass (mg) Mass (%) 
   
A 28.0 0.42 
B 36.4 0.55 
C 17.8 0.27 
D 65.1 0.98 
E 8.4 0.13 
F 6.1 0.09 
G 22.0 0.33 
H 421.3 6.32 
I 4639.3 69.58 
I2 1423.3 21.35 
Total 6666.7  
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Figure 16. Inhibition halos of the antimicrobial active VLC fractions: (A) fraction D, (B) fraction E, 
(C) fraction F, (D) fraction G, and (E) fraction I2.  
 
In the assay of anticancer activity, none of the fractions was able to decrease the 
viability of the cells lines neuroblastoma SH5Y-SH and breast ductal carcinoma T-47D 
to values below 50% (Figs. 17A and 17B). Nevertheless, the fractions that seemed to 
have a greater potential were fraction D that led to a decrease in the viability of the cell 
line SH5Y-SH to 59% after 48 h of exposure, and fraction H that decreased the viability 
of the cell line T-47D for 57% after 48 h of exposure (Fig. 17B).  
 
 
 
 
 
 
Figure 17. MTT results of VLC fractions. The graphs show the cellular viability after 24 and/or 48 h of exposure for (A) 
SH5Y-SH, (B) T-47D cell lines. PC and NC indicate positive and negative controls, respectively. Error bars represent 
standard deviation of the mean of at least duplicate assays. 
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At this point attention became focused on the antimicrobial activity of the fractions, 
that proved to be more relevant than the anticancer activity. The active fractions (D, E, 
F, G and I2) and the adjacent ones (C, H and I) were selected to 1H NMR analysis. This 
analysis showed that the profiles of fractions D, E, F, and G are more similar to each 
other, as are those of fractions I and I2. The fractions C and H appear to be the ones 
that differ most from the rest (Fig. 18). 
Figure 18. 1H NMR spectra of Streptomyces sp. KENR25 VLC fractions C-I2. 
 
According to the results of the antimicrobial assay and the 1H NMR data it was decided 
to proceed with fractions D, E, F, and G. These 4 fractions were pooled and processed 
as a single fraction (DEFG), totalizing a mass of 101.64 mg. DEFG fraction was further 
fractionated by FC, assisted by TLC. From this procedure, 9 fractions (DEFG-A - DEGF-
I) were generated (Table 7) and, bearing in mind the DEFG fraction and the mass of 
each sub-fraction, the yield of the procedure was approximately 96.8%. Once again, all 
the fractions were tested for their activity against C. albicans and 5 fractions - DEFG-A - 
DEFG-E – showed to be able to inhibit the growth of this microorganism, with inhibition 
halos between 13 and 25 mm of diameter. All the halos presented a diffuse appearance 
(Fig. 19).  
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Table 7. FC fractions with the indication of the mass amount yield for each one 
 
Fraction Mass (mg) Mass (%) 
   
DEFG-A 23.8 24.26 
DEFG-B 18.2 18.48 
DEFG-C 14.8 15.03 
DEFG-D 6.3 6.40 
DEFG-E 1.9 1.93 
DEFG-F 4.3 4.37 
DEFG-G 4.1 4.16 
DEFG-H 14.5 14.72 
DEFG-I 10.5 10.66 
Total 98.5  
   
  
 
Figure 19. Inhibition halos caused by of the antimicrobial active FC fractions: (A) fraction DEFG-A, 
(B) fraction DEFG-B, (C) fraction DEFG-C, (D) fraction DEFG-D and (E) fraction DEFG-E.  
 
The active fractions were again subjected to 1H NMR analysis (Fig. 20). According to 
the similarity of the obtained spectra it was considered that the fractions DEFG-A and 
DEFG-B should be processed individually, and the remainder could eventually be 
grouped. 
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Figure 20. 1H NMR spectra of Streptomyces sp. KENR25 FC fractions DEFG-A – DEFG-E. 
 
The five active DEFG fractions were also analysed by LC-MS/MS. The resultant files 
were uploaded to GNPS directory and two protocols were performed: data analysis and 
dereplication. According to the results of these procedures and, focusing on the 
elucidation of the molecules responsible for the bioactivity of the strain, the compounds 
present in the sample that stood out were the antibiotics Antimycin A2, A3, and A4. Using 
the MS/MS data, a molecular networking was also developed in Cytoscape (Fig. 21).   
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Figure 21. Molecular networking developed with the MS/MS data obtained for the fractions DEFG-A – DEFG-E. (A) 
Complete molecular networking and (B) cluster corresponding to the antimycins. The numbers within the nodes 
correspond to the mass of each fragment. The size of the nodes indicates the abundance of the fragment. The similarity 
between two nodes was computed based on the cosine score defining the connecting edges. The colours match the 
fragments found in each of the DEFG sub-fractions. 
 
Regarding all data - 1H NMR, LC-MS/MS, antimicrobial activity in the assay, amount 
of available mass and simplicity of the sample - DEFG-A fraction was selected for HPLC 
fractionation. From this procedure 10 fractions were obtained (DEFG-A-A – DEFG-A-J) 
(Table 8), according to the peaks recorded in the spectra (Fig. 22). Concerning the 
DEFG-A fraction and the mass of each sub-fraction, the yield of the procedure was 
approximately 72.4 %. Each fraction will be later tested for its action against the growth 
of C. albicans, following the procedures already described for this bioassay. 
 
 
 
B 
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Table 8. HPLC fractions with the indication of the mass amount yield for each one (BL - baseline) 
 
Fraction Mass (mg) Mass (%) 
   
DEFG-A-A 0.1 0.58 
DEFG-A-B 0.2 1.16 
DEFG-A-C 0.7 4.05 
DEFG-A-D 1.5 8.67 
DEFG-A-E 2.3 13.29 
DEFG-A-F 0.3 1.73 
DEFG-A-G 0.2 1.16 
DEFG-A-H 0.1 0.58 
DEFG-A-I 0.1 0.58 
DEFG-A-J 11.2 64.74 
BL 0.6 3.47 
Total 17.3  
 
Figure 22. HPLC chromatogram of the peaks corresponding to the fractions DEFG-A-A to DEFG-A-J. 
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IV. Discussion 
 
 
Macroalgae offer a wealthy habitat for several epiphytic and endophytic 
microorganisms [118]. Although actinobacterial endophytes of terrestrial plants have been 
proven to be a valuable source of bioactive compounds [119, 120] , their presence and 
diversity in macroalgae and their biotechnological potential is largely unknown. The 
collection of microorganisms previously isolated from the kelp L. ochroleuca, revealed to 
contain a high number of actinobacterial strains, indicating that this macroalgae is a rich 
reservoir of actinobacteria. Although it is not possible to guarantee that the recovered 
isolates are all endophytes (the disinfection process was not entirely effective), only five 
isolates grew in the disinfection control plates and none was identified as Actinobacteria. 
Achieving complete microbial sterilization of an organism's surface, such as algae or 
plants, is difficult and rarely achieved. Several studies focusing on the isolation of 
endophytic microorganisms have been trying to optimize the disinfection methods, but in 
general were unable to obtain total efficiency [113, 121, 122]. The efficiency of our sterilization 
method is in line with the pattern of results generally obtained with these procedures. 
Though the endophytic nature of the actinobacterial strains isolated from L. ochroleuca 
could not be completely established, the low number of isolates grown in the disinfection 
controls leads us to accept that many of the recovered strains are in fact endophytes.  
The majority of the isolated strains was obtained from holdfasts of L. ochroleuca, 
which may result from the permanent contact of this part of the algae with marine 
sediments or coastal rocks, where actinobacteria are known to predominate [22, 123]. The 
largest fraction of actinobacterial isolates was recovered from the culture medium SCN, 
followed by the RH medium. The success of these media in the recovering of marine 
actinobacteria has been reported in other studies, reason why they were chosen for the 
isolation process [124, 125]. The NPS medium allowed a lower recovery of actinobacteria 
from L. ochroleuca, which may be due to the poor nutrients composition of this medium, 
suggesting that actinobacteria associated with this kelp species may prefer richer carbon 
sources to grow. 
The 16S rRNA gene sequencing analysis revealed that most of the recovered isolates 
(84%) were affiliated with the genus Streptomyces. Microorganisms belonging to this 
genus have been frequently isolated from several marine ecological niches [126, 127]. It is 
quite promising to have isolated so many Streptomyces strains from L. ochroleuca 
considering that this genus is the most important source of bioactive molecules. Previous 
studies have also reported the isolation of several Streptomyces strains with notorious 
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biological activity from various algae species, including species belonging to the class 
Phaeophyceae where L. ocholeuca belongs [108, 128, 129]. Streptomyces are amongst the 
actinobacteria most commonly isolated and cultivated under laboratory conditions [127, 
128]. Nonetheless, the experimental approach adopted in the present study also allowed 
the isolation of actinobacterial strains affiliated with six rare actinobacterial genera – 
Isoptericola, Rhodococcus, Nonomuraeae, Nocardiopsis, Microbispora and 
Microbacterium. Rare actinobacterial genera are gaining increasing attention in the field 
of drug discovery owning to their underexplored metabolic potential [130-132]. Some of the 
rare actinobacterial genera identified in the present study, namely Isoptericola, 
Nocardiopsis and Microbacterium, have also been isolated from other macroalgae 
species, including some from the class Phaeophyceae [133-136]. The bioactivity assays 
revealed that half of the total recovered strains exhibited antimicrobial activity. Most of 
these isolates showed antifungal activity against C. albicans, with four Streptomyces 
strains exhibiting the highest activities (inhibition halos > 20 mm and MIC values between 
< 0.487 and 1.95 μg/mL). Streptomyces strains isolated in other studies from diverse 
marine sources have also been reported to produce secondary metabolites with 
antifungal properties against C. albicans, like isoikarugamycin, a novel polycyclic 
tetramic acid macrolactam produced by Streptomyces zhaozhouensis, with a MIC value 
of 2–4 μg/mL [137] or saadamycin, a polyketide produced by a marine sponge-associated 
Streptomyces sp., with a MIC value of 1–5 μg/mL [80]. Eight actinobacterial strains 
isolated in the present study also exhibited antibacterial activity against S. aureus, 
showing inhibition halos of 10-20 mm and MIC values between 3.90 and 7.81 μg/mL. 
These results are promising, considering that S. aureus is a human pathogen 
responsible for an extensive range of clinical infections, some of them associated with 
resistance to antibiotics, constituting an important target for the development of novel 
therapeutic agents [138]. The capacity of marine actinobacteria to produce secondary 
metabolites active against S. aureus has also been previously reported, as is the case 
of the compounds arenimycin and abyssomicin C, two antibiotics produced respectively 
by Salinispora and Verrucosispora strains, active against multidrug-resistant S. aureus 
and with MIC values of < 1 and 13 μg/mL, respectively [98, 139]. Recently, an actinobacterial 
strain identified as Kocuria marina CMG S2, isolated from the brown macroalgae Pelvetia 
canaliculata, was reported to produce a novel antibiotic, named as kocumarin, exhibiting 
notorious activity against fungi and pathogenic bacteria, including methicillin-resistant S. 
aureus [109]. 
In this study, the anticancer activity of all actinobacterial isolates was also tested 
against two human carcinogenic cell lines – neuroblastoma SH-SY5Y and breast ductal 
carcinoma T-47D. A total of 30 extracts demonstrated capacity to decrease the viability 
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of the cell lines by more than 50% (at 15 µg/mL) and, in some cases, to values 
approaching 0%, after 24 h or 48 h of exposure (Fig. 15). Many of those potent extracts 
demonstrated cytotoxicity also on the non-carcinogenic cell line hCMEC/D3, which 
indicates general cytotoxicity. However, some of the extracts with strong anticancer 
activity did have little impact on non-tumour cells, showing an interesting specificity 
towards neuroblastoma cells (KENR18, KENR25, KENR59, KENR91). These results 
suggest that some of the isolates might produce secondary metabolites with strong 
cytotoxicity towards cancer cells, which should be explored in future works. Marine 
actinobacteria have been already recognised as prolific producers of anticancer 
compounds, with an increasing number of studies reporting actinobacterial strains 
isolated from different marine sources, including macroalgae, capable of producing 
secondary metabolites with anticancer activity [25, 100, 110, 139]. Many of these strains are 
Streptomyces but genera exclusive from marine environments like Salinispora, 
Salinibacterium or Marinispora are also wealthy reservoirs of promising anticancer 
molecules [25, 140]. 
According to the dereplication procedure, where the metabolomic profile of 35 crude 
extracts with bioactive properties was investigated, it was possible to notice that 
antimycins were the mostly abundant compounds. In natural products research, 
dereplication is an imperative step since it allows to understand if the active compounds 
present in a sample might be or not already known [141]. Antimicyins are a group of 
bioactive secondary metabolites exhibiting antifungal activity that were isolated for the 
first time in 1949 from a soil Streptomyces strain [142]. This substance was initially named 
as antimycin A, but later it was proved that this was a mixture of at least four bioactive 
components, named as antimycin A1, A2, A3 and A4 [143]. To date, more than 40 naturally 
occurring antimycins, and additional ring-expanded antimycins, have been isolated [144]. 
Since their initial isolation, antimicyins have been target of extensive research for their 
powerful and diverse biological activities. As a result of their ability to inhibit mitochondrial 
electron transport chains [145, 146], these macrolide antibiotics have been shown to have 
antifungal, insecticidal, nematocidal, and piscicidal properties [147-149]. In addition to all 
these biological features, some classes of antimycins have also proved to have 
promising anticancer and anti-inflammatory activities [144, 150, 151]. Antimycins-producing 
actinobacteria have been isolated from numerous environments, including marine 
ecosystems, with marine Streptomyces being especially preponderant in the synthesis 
of this antibiotic [152-154]. Considering the established antimicrobial and anticancer 
properties of the antimycins, their presence in 26 out of the 35 extracts selected in this 
study for dereplication is the most likely explanation for the biological activities observed 
(Table 5). The occurrence of this antibiotic in so many extracts raised the question of a 
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possible contamination during the analysis, however, extracts of cyanobacteria were 
concomitantly examined during the same experimental procedure and, for these 
extracts, the presence of antimycins was not detected, allowing validating the 
dereplication results. Although the synthesis of antimycins is usually associated with 
Streptomyces, from the dereplication data it was possible to verify that strains belonging 
to other genera - Isoptericola (KENR84), Microbacterium (KENB10), Microbispora 
(KENS2) - also seem to produce them. In addition, there was no correlation between the 
part of the macroalgae from which the actinobacterial strains were isolated and the 
production of antimycin, since strains isolated from the holdfast, stipe and blade of L. 
ochroleuca seem to be producers of these metabolites. It may be speculated that 
macroalgae represents a favourable ecological niche for the synthesis of antimycins, not 
only by Streptomyces but also by other actinobacteria, however these two assumptions 
are still unclear and may represent future research paths. Apart from identifying the 
bioactive compounds most probably present in the extracts, dereplication also allows 
selecting the more promising strains for the eventual discovery of novel bioactive 
compounds. Therefore, when early used in NPs research, dereplication can minimize 
time, effort, and costs [155]. The fact that the bioactivities of nine actinobacterial extracts 
could not be attributed to a known active secondary metabolite in the dereplication 
process, makes these extracts the most promising ones for future research. All these 
extracts were derived from Streptomyces strains – KENR31, KENR59, KENR60, 
KENR64, KENR65, KENR85, KENR86, KENR91 and KENRB1 – and displayed strong 
bioactivities that may possibly be associated with compounds not yet described. By 
analysing the bioactivity results of these isolates (Table 4, Fig. 15, Annex 2), it is possible 
to observe that these strains display a very dissimilar profile: KENR31 have antimicrobial 
activity against both C. albicans and S. aureos (MIC values of 62.5 and 500 μg/mL, 
respectively); KENR59 has anticancer activity, decreasing SH5Y-SY cells viability to 
values below 10%; KENR65 exhibits both antifungal and anticancer activity, being 
effective against C. albicans (MIC of 125 μg/mL) and decreasing SH5Y-SY and T-47D 
cells viability for values below 3%; KENR85 holds anticancer activity, decreasing SH5Y-
SY cells viability to values below 31%; KENR86 has antifungal activity against C. 
albicans (MIC of 1 mg/mL); KENB1 has anticancer activity, decreasing both SH5Y-SY 
and T-47D cells viability to values below 3%; KENR60 and KENR64 are the most similar 
strains in terms of bioactivity, as both display antibacterial activity against S. aureus (MIC 
of 3.9 μg/mL) and anticancer activity against SH5Y-SY and T-47D cells, decreasing their 
viability to values below 5%. In this scenario, the investigation of the bioactive 
compounds present in the extracts from strains KENR85 and KENR86 may not be a 
priority, as their activities are not as outstanding as those of the remaining extracts, but 
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all nine strains mentioned here would be important for future research on bioactive NPs 
prospecting.  
Streptomyces sp. KENR25 was selected for a bioactivity-guided study of the 
produced bioactive molecules. A strategy based on the traditional natural product 
discovery pipeline was applied. The strain selection was made before the dereplication 
procedure, being the presence of antimycin in its extract not yet known. Focusing on the 
antimicrobial activity of the strain, it was verified that the capacity of inhibiting C. albicans 
growth was preserved throughout the fractionation procedures. In the initial assay, the 
strain’s crude extract presented an inhibition halo with a diameter of 22 mm and a MIC 
value < 0.487 (Table 4, Fig. 14). From the VLC fractionation, 5 active fractions - D, E, F, 
G and I2 – were obtained, with inhibition halos between 15-19 mm of diameter (Fig. 16). 
From the FC fractionation, also 5 active fractions - DEFG-A, DEFG-B, DEFG-C, DEFG-
D and DEFG-E - were obtained, with inhibition halos between 13-25 mm of diameter 
(Fig. 19). In contrast with antimicrobial activity, it seems that anticancer activity was lost 
with the fractionation process. In the initial anticancer assays, the performance of 
KENR25 was very strong, especially when the crude extract was tested on the SH-SY5Y 
cell line, where the viability of the cells decreased to values below 10%. In the T-47D cell 
line, the cellular viability decreased to values below 36%. However, the best values 
obtained with the VLC fractions were 59% (fraction D) and 57% (fraction H), for SH-
SY5Y and T-47D cells viability, respectively (Fig. 17). To complement the bioactivity 
results, a molecular networking of the active antimicrobial FC fractions was developed. 
Molecular networking is an organizational approach to MS/MS data that has been 
recently introduced in the drug discovery field. Among its various applications, it allows 
to identify unknown natural products with potential pharmaceutical significance. This 
approach relies on the molecules chemistry: two related molecules are likely to share 
similar MS/MS fragmentation patterns, being a molecular network a visual representation 
of the molecular relatedness (chemical similarity) of any set of compounds [155, 156]. This 
tool has been increasingly used in the search for novel bioactive compounds, namely 
produced by marine actinobacteria [157]. By examining the molecular network, it was 
possible to observe the cluster corresponding to antimycin (Fig. 21B), as would be 
expected according to the dereplication data. Nevertheless, in this cluster several nodes 
with slightly different masses from those corresponding to antimycins A2 and A3 occur. 
Some of these might correspond to internal fragments and adducts formed during MS 
analysis, but others may possibly be new antimycin analogues (a few dozen have 
already been described, so the existence of more is conceivable). From the molecular 
networking it was also possible to infer that KENR25 may produce other active 
metabolites than antimycins due to the presence of other unidentified clusters. A more 
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detailed study will be necessary in order to evaluate their abundance and distribution 
within the fractions, but they can be associated with a novel secondary metabolite. The 
strategy applied for KENR25 strain may be used in the future with promising strains, 
namely those for which the replication process found no known compounds, leading 
eventually to the discovery of a novel bioactive substance. 
The combination of microbiology, molecular biology, chemistry and in silico 
techniques allowed to understand the bioactive potential of endophytic actinobacteria 
associated with the macroalgae L. ochroleuca. Although challenging and demanding, the 
possibility of discovering, isolating and characterizing a new pharmaceutically relevant 
compound from the studied strains remains open. 
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V. Conclusion 
 
 
The objective of this MSc thesis was to investigate the community of endophytic 
actinobacteria associated with the macroalgae L. ochroleuca and its respective 
antimicrobial and anticancer potential. The results presented here suggest that marine 
macroalgae, such as L. ochroleuca, represent a valuable source of actinobacteria, both 
in terms of abundance and diversity and of natural products with powerful bioactivities. 
Using an interdisciplinary approach, it was possible not only to evaluate the antimicrobial 
and anticancer potential of the 90 actinobacterial strains isolated from the studied 
macroalgae, but also to understand the main compounds responsible for their 
bioactivities and realise that some of the metabolites produced by them may not yet have 
been described and constitute new compounds. 
In conclusion, this work adds to the yet-meagre knowledge available on actinobacteria 
associated with marine macroalgae and their bioactive potential. The promising results 
presented in this thesis pave the way for further studies, namely the analysis of the 
chemical composition of the bioactive extracts for the identification of the chemical 
entities responsible for the observed activities.  
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141. Nielsen, K.F., M. Månsson, C. Rank, J.C. Frisvad, and T.O. Larsen, Dereplication 
of microbial natural products by LC-DAD-TOFMS. Journal of natural products, 
2011. 74(11): p. 2338-2348. 
142. Dunshee, B.R., C. Leben, G. Keitt, and F. Strong, The isolation and properties of 
antimycin A. Journal of the American Chemical Society, 1949. 71(7): p. 2436-
2437. 
143. Yang, Y.-Q. and Y. Wu, Synthesis of antimycins. A review. Organic preparations 
and procedures international, 2007. 39(2): p. 135-152. 
144. Liu, J., X. Zhu, S.J. Kim, and W. Zhang, Antimycin-type depsipeptides: discovery, 
biosynthesis, chemical synthesis, and bioactivities. Natural product reports, 
2016. 33(10): p. 1146-1165. 
145. Rasimus-Sahari, S., R. Mikkola, M.A. Andersson, M. Jestoi, and M. Salkinoja-
Salonen, Streptomyces strains producing mitochondriotoxic antimycin A found in 
cereal grains. International journal of food microbiology, 2016. 218: p. 78-85. 
146. Slater, E., The mechanism of action of the respiratory inhibitor, antimycin. 
Biochimica et Biophysica Acta (BBA)-Reviews on Bioenergetics, 1973. 301(2): p. 
129-154. 
147. Hosotani, N., K. Kumagai, H. Nakagawa, T. Shimatani, and I. Saji, Antimycins A 
10∼ A 16, seven new antimycin antibiotics produced by Streptomyces spp. SPA-
10191 and SPA-8893. The Journal of antibiotics, 2005. 58(7): p. 460. 
148. Lennon, R.E. and C. Vézina, Antimycin A, a Piscicidal Antibiotic1, in Advances in 
applied microbiology. 1973, Elsevier. p. 55-96. 
149. Shiomi, K., K. Hatae, H. Hatano, A. Matsumoto, Y. Takahashi, C.-L. Jiang, H. 
Tomoda, S. Kobayashi, H. Tanaka, and S. Ōmura, A new antibiotic, antimycin A 
9, produced by Streptomyces sp. K01-0031. The journal of antibiotics, 2005. 
58(1): p. 74. 
150. Arsianti, A., H. Tanimoto, T. Morimoto, and K. Kakiuchi, Design and molecular 
docking study of antimycin A3 analogues as inhibitors of anti-apoptotic Bcl-2 of 
breast cancer. Open Journal of Medicinal Chemistry, 2014. 4(3): p. 79. 
151. Strangman, W.K., H.C. Kwon, D. Broide, P.R. Jensen, and W. Fenical, Potent 
inhibitors of pro-inflammatory cytokine production produced by a marine-derived 
bacterium. Journal of medicinal chemistry, 2009. 52(8): p. 2317-2327. 
FCUP 
Endophytic Actinobacteria from Laminaria ochroleuca: a new source of bioactive compounds 
64 
 
152. Han, Z., Y. Xu, O. McConnell, L. Liu, Y. Li, S. Qi, X. Huang, and P. Qian, Two 
antimycin A analogues from marine-derived actinomycete Streptomyces 
lusitanus. Marine drugs, 2012. 10(3): p. 668-676. 
153. IMAMURA, N., M. NISHIJIMA, K. ADACHI, and H. SANO, Novel antimycin 
antibiotics, urauchimycins A and B, produced by marine actinomycete. The 
Journal of antibiotics, 1993. 46(2): p. 241-246. 
154. Xu, L.-Y., X.-S. Quan, C. Wang, H.-F. Sheng, G.-X. Zhou, B.-R. Lin, R.-W. Jiang, 
and X.-S. Yao, Antimycins A 19 and A 20, two new antimycins produced by 
marine actinomycete Streptomyces antibioticus H74-18. The Journal of 
antibiotics, 2011. 64(10): p. 661. 
155. Yang, J.Y., L.M. Sanchez, C.M. Rath, X. Liu, P.D. Boudreau, N. Bruns, E. 
Glukhov, A. Wodtke, R. De Felicio, and A. Fenner, Molecular networking as a 
dereplication strategy. Journal of natural products, 2013. 76(9): p. 1686-1699. 
156. Quinn, R.A., L.-F. Nothias, O. Vining, M. Meehan, E. Esquenazi, and P.C. 
Dorrestein, Molecular networking as a drug discovery, drug metabolism, and 
precision medicine strategy. Trends in pharmacological sciences, 2017. 38(2): p. 
143-154. 
157. Duncan, K.R., M. Crüsemann, A. Lechner, A. Sarkar, J. Li, N. Ziemert, M. Wang, 
N. Bandeira, B.S. Moore, and P.C. Dorrestein, Molecular networking and pattern-
based genome mining improves discovery of biosynthetic gene clusters and their 
products from Salinispora species. Chemistry & biology, 2015. 22(4): p. 460-471. 
 
  
FCUP 
Endophytic Actinobacteria from Laminaria ochroleuca: a new source of bioactive compounds 
65 
 
VII. ANNEX 
 
Annex 1. Identification and bioactive profile of all actinobacterial strains isolated from L.ochroleuca. 
     
STRAIN 16S rRNA 
ANTIMICROBIAL ASSAY ANTICANCER ASSAY 
DEREPLICATION 
S. aureus C. albicans SH-SY5Y T-47D hCMEC/D3 
Inhibition 
Halo (cm) 
MIC 
(µg/mL) 
Inhibition 
Halo (cm) 
MIC 
(µg/mL) 
Cellular 
Viability 
(% 24 h) 
Cellular 
Viability 
(% 48 h) 
Cellular 
Viability 
(% 24 h) 
Cellular 
Viability 
(% 48 h) 
Cellular 
Viability 
(% 24 h) 
Cellular 
Viability 
(% 48 h) 
             
KENR1 Streptomyces aureus - - - - 92 87 94 77 - - - 
KENR3 Streptomyces olivochromogenes - - 1 31.25 95 93 86 88 - - - 
KENR4 Streptomyces olivochromogenes - - - - 95 69 81 70 - - - 
KENR5 Streptomyces sp. - - - - 100 100 92 85 - - - 
KENR6 Streptomyces sp. 1 1000 1.8 0.975 87 36 77 60 67 51 Antimycin A2, A3 
KENR7 Streptomyces sp. - - - - 90 63 80 58 - - - 
KENR8 Streptomyces atratus - - 1.7 1.95 100 94 79 86 - - Antimycin A2 
KENR10 Streptomyces diastaticus - - - - 68 56 83 69 - - - 
KENR11 Streptomyces diastaticus - - - - 99 97 100 99 - - - 
KENR11A Streptomyces sp. - - 2 7.81 68 57 78 48 65 47 - 
KENR13 Streptomyces sp. - - 1.7 1.95 77 58 70 57 - - Antimycin A2, A3 
KENR13A Streptomyces sp. - - 2.5 0.975 86 72 70 57 - - Antimycin A2, A3 
KENR13B Streptomyces sp. 1 1000 1.2 7.81 89 70 75 67 - - 
Antimycin A1, A2, A3, 
A4 
KENR13C Streptomyces iastaticus - - - - 100 88 98 100 - - - 
KENR14 Streptomyces iamenensis - - 1.1 7.81 100 53 76 64 - - Antimycin A2 
KENR16A Streptomyces thermoiolaceus - - - - 70 49 65 46 76 69 - 
KENR16B Streptomyces sp. - - 1.2 15.62 95 97 87 71 - - - 
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KENR17A Streptomyces sp. - - 2 1.95 48 46 53 43 50 44 Antimycin A2, A3 
KENR17B Streptomyces sp. - - - - 55 42 55 39 - - - 
KENR18 Streptomyces sp. 0.8 1000 1.8 0.975 58 3 31 33 73 48 Antimycin A2, A3 
KENR19 Streptomyces sp. - - 2 0.975 96 79 73 66 - - - 
KENR21 Streptomyces sp. - - 1.3 1.95 99 77 87 68 - - - 
KENR21A Streptomyces sp. - - 2 0.975 99 73 80 52 - - Antimycin A2, A3 
KENR23A Streptomyces sp. - - - - 97 55 73 72 - - - 
KENR23B Streptomyces achromogenes - - - - 90 81 74 81 - - - 
KENR23C Streptomyces sp. - - - - 100 71 86 76 - - - 
KENR23D Streptomyces sp. - - - - 39 72 88 81 70 67 - 
KENR24 Streptomyces sp. - - 0.8 7.81 96 75 90 74 67 44 - 
KENR25 Streptomyces sp.   2.2 < 0.487 9 2 36 34 76 27 Antimycin A2, A3 
KENR26 Streptomyces sp. - - - - 88 38 81 66 - - - 
KENR27 Streptomyces sp. - - - - 100 98 87 89 - - - 
KENR28 Streptomyces atratus - - - - 99 91 100 93 - - - 
KENR29 Nonomuraea sp. - - 1.4 3.9 50 56 71 77 - - Antimycin A2, A3 
KENR30 Nocardiopsis prasina - - - - 59 58 64 57 - - - 
KENR31 Streptomyces sp. 1 500 1.3 62.5 55 32 76 56 69 70 No Match 
KENR32 Streptomyces achromogenes - - - - 91 90 98 89 - - - 
KENR33 Streptomyces lannensis - - 2.3 1.95 76 48 66 44 55 43 Antimycin A2, A3 
KENR34 Streptomyces sp. - - 2 15.62 100 64 81 54 - - - 
KENR35 Streptomyces sp. - - 2.5 0.975 61 22 58 50 62 43 Antimycin A2, A3 
KENR36 Streptomyces sp. - - 1 125 89 76 72 65 - - - 
KENR38 Streptomyces flaveolus - - - - 57 57 75 86 - - - 
KENR39 Rhodococcus erythropolis - - - - 44 58 68 74 72 66 - 
KENR40 Streptomyces sp. - - - - 98 88 90 82 - - - 
KENR41 Streptomyces tenae - - - - 100 95 89 90 - - - 
KENR42 Streptomyces mirabilis - - 1 125 89 68 100 96 - - - 
KENR45A Streptomyces sp. - - - - 100 71 92 89 - - - 
KENR47 Streptomyces sp. - - - - 100 71 75 77 - - - 
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KENR49 Streptomyces atratus - - 1.8 3.9 70 53 72 71 - - Antimycin A2 
KENR50 Streptomyces sanglieri - - - - 73 54 68 60 - - - 
KENR51 Streptomyces sanglieri - - - - 79 62 77 80 - - - 
KENR52 Streptomyces mirabilis - - - - 94 78 87 85 - - - 
KENR55 Streptomyces sp. - - - - 100 78 94 95 - - - 
KENR57 Streptomyces sp. - - - - 59 47 71 71 72 70 - 
KENR59 Streptomyces sp. - - - - 8 10 67 32 43 42 No Match 
KENR60 Streptomyces sp. - - 2.1 3.9 0 1 4 0 0 0 No Match 
KENR64 Streptomyces sp. - - 2 3.9 1 1 5 0 0 0 No Match 
KENR65 Streptomyces sp. 1.2 125 - - 0 0 3 0 0 0 No Match 
KENR69 Streptomyces sp. 1.2 15.62 - - 73 56 72 61 - - - 
KENR70 Nocardiopsis prasina 1 15.62 - - 94 83 66 45 66 51 - 
KENR71 Streptomyces brevispora - - - - 49 66 75 81 74 74 - 
KENR72 Streptomyces aureus - - 1.7 1.95 100 68 78 71 74 74 Antimycin A2, A3 
KENR74 Streptomyces sp. - - 1.6 1.95 31 30 71 67 61 47 Antimycin A2, A3 
KENR75 Streptomyces sp. - - - - 85 82 100 100 - - - 
KENR76 Rhodococcus erythropolis - - - - 62 59 69 75 - - - 
KENR77 Streptomyces sp. - - 2 < 0.487 100 72 83 66 - - Antimycin A2, A3 
KENR78 Rhodococcus sp. - - - - 55 46 72 73 64 52 - 
KENR79 Streptomyces sp. - - 1.8 0.975 27 31 70 65 58 46 - 
KENR80 Streptomyces sp. - - 1.2 15.82 85 32 62 53 59 49 Antimycin A2, A3 
KENR81 Streptomyces sp. - - 1.5 3.9 27 19 65 63 58 51 Antimycin A1, A2, A3 
KENR82 Isoptericola chiayiensis - - - - 100 62 82 77 - - - 
KENR84 Isoptericola sp. - - 1.8 3.9 73 78 74 76 - - Antimycin A1, A3 
KENR85 Streptomyces diastaticus - - - - 21 31 100 100 95 90 No Match 
KENR86 Streptomyces sp. - - 1.6 1000 100 100 92 89 - - No Match 
KENR87 Streptomyces xiamenensis - - - - 83 83 84 82 - - - 
KENR89 Streptomyces atratus - - - - 97 97 77 70 - - - 
KENR90 Nocardiopsis prasina - - - - 90 94 77 100 - - - 
KENR91 Streptomyces sp. - - - - 12 6 89 81 64 66 No Match 
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KENR92 Streptomyces sp. - - - - 95 92 100 100 - - - 
KENR93 Microbacterium testaceum - - 1.5 7.81 100 63 88 88 - - - 
KENR94 Streptomyces sp. - - 1.7 7.81 1 0 10 10 6 8 Antimycin A3 
KENS1 Microbacterium testaceum - - - - 55 57 90 62 - - - 
KENS2 Microbispora bryophytorum - - 1.2 1.95 100 86 100 90 - - Antimycin A2 
KENB1 Streptomyces atratus - - - - 2 0 3 3 0 0 No Match 
KENB3 Streptomyces sp. - - 1.3 7.81 100 80 100 84 - - Antimycin A2, A3 
KENB5 Streptomyces sp. - - - - 100 97 95 90 - - - 
KENB6 Streptomyces sp. - - - - 86 91 69 68 - - - 
KENB7 Microbacterium testaceum - - - - 100 87 100 88 - - - 
KENB8 Streptomyces sp. - - 1 500 65 59 82 80 - - - 
KENB9 Streptomyces sp. - - 1.5 3.9 100 56 88 87 - - Antimycin A2 
KENB10 Microbacterium testaceum 1 1000 1 250 86 40 68 46 68 67 Antimycin A2 
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Annex 2. Phylogenetic relationship of the 41 actinobacterial isolates considered for dereplication, based 
on 16S rRNA gene homology. DNA sequences of the isolates were aligned using the Geneious software, 
version 11.1.4, resulting in an alignment with 1240 bp. The phylogenic tree was made using the Maximum 
Likelihood method with 1000 bootstraps based on the Tamura-Nei model. The tree was constructed using 
the Molecular Evolutionary Genetics Analysis Program, Version 7.0 (MEGA7). Numbers at nodes represent 
the percentage levels of bootstrap support. 
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